A coronavirus vaccine designed entirely by artificial intelligence has passed its first test in humans. The results, announced June 5, 2026, and published in the Journal of Infection, showed the vaccine is safe, well-tolerated, and capable of generating immune responses against multiple coronavirus strains, including SARS-CoV-2 and related bat viruses with pandemic potential.
It is a genuine milestone. It is also an early Phase 1 trial in 39 people. Clinical approval is years away.
For the many Americans who are considering whether to get this fall's COVID booster or wait for a more comprehensive vaccine, the honest answer is: do not wait.
Why This Matters
Every COVID vaccine deployed since 2020 was designed to target the spike protein of a specific virus strain. As new variants emerge with mutations in the spike protein, vaccine effectiveness diminishes, which is why annual reformulation and periodic boosters have become routine.
The pEVAC-PS vaccine, developed by the University of Cambridge and its spinout company DIOSynVax, takes a different approach. An AI system analyzed the genetic sequences of known coronaviruses and computationally selected antigens with high conservation across strains — meaning they are less likely to mutate, making the immune response potentially durable against many variants, including ones that do not yet exist.
If this approach ultimately works at scale, it could eliminate the need for annual COVID vaccine reformulation and potentially protect against future pandemic coronaviruses before they emerge. "The current reactive vaccine system struggles to keep pace, making this new class of universal vaccines essential," said Professor Saul Faust, the trial's chief investigator, according to NewsCord.
What We Know So Far
The Phase 1 trial enrolled 39 healthy adults between 18 and 50 years old who had previously received COVID-19 vaccines. Participants received four escalating doses of the vaccine (0.2 mg, 0.4 mg, 0.8 mg, or 1.2 mg) delivered via a needle-free jet system at day zero and day 28.
According to ScienceDaily, the trial showed no serious adverse events at any dose level. All participants were immunologically active — they mounted measurable responses to the conserved viral targets the vaccine was designed to protect against, including SARS-CoV-2, SARS, and related bat viruses that have not yet infected humans.
This is the first time a vaccine whose active component was designed entirely by computer simulations has been tested in humans, and the first needle-free delivery of this type of DNA vaccine in a human trial.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Study type: Open-label Phase 1 dose-escalation safety trial
- Participants: 39 healthy adults, ages 18–50, all with prior COVID vaccination history
- Published in: Journal of Infection (June 5, 2026)
- What it found: Safe, well-tolerated at all four doses; immune responses against multiple coronavirus strains, including bat coronaviruses
- Important limitation: This was an open-label trial with no placebo group. All participants had high pre-existing antibody levels from prior COVID vaccines and recent Omicron infections. Measuring the vaccine's added immunological contribution against a high baseline is inherently difficult.
- What it did not prove: Efficacy against actual coronavirus infection; effectiveness in preventing disease; effectiveness in diverse or older populations; durability of immune response over time
- Current status: Phase 2 trial in planning; no Phase 3 data; no regulatory submission timeline announced
As one expert commentary noted: "The immune response was modest, but I would not read too much into that yet. Almost everyone in this trial already had strong antibody levels from past COVID-19 shots and from Omicron waves happening during the study. When people start with a lot of immunity, it is hard to see what a new vaccine adds."
The Honest Timeline
Phase 1 trials answer one question: is this safe enough to keep studying? This one answered yes.
Phase 2 trials — which test whether the vaccine produces the immune responses it was designed to generate in a broader and more diverse population — are next. They have not yet begun.
Phase 3 trials — which test whether the vaccine actually prevents COVID infection and disease — are years away.
After Phase 3, a regulatory submission to the FDA and other agencies, agency review, and manufacturing scale-up would need to occur. For a truly novel vaccine platform targeting a broad population, history suggests the full process from a promising Phase 1 result to an FDA-approved product typically takes three to seven years — often longer.
For context: the COVID-19 mRNA vaccines were developed with Operation Warp Speed funding, emergency manufacturing commitments, and regulatory expediting at an unprecedented scale — and still took approximately a year from the start of large-scale trials to emergency authorization. The pEVAC-PS vaccine is at the very beginning of that process.
What Doctors and Experts Say
Vaccine scientists have characterized the Phase 1 results as encouraging proof of concept for the AI-based antigen design approach — not a near-term public health solution. The primary value of this trial is demonstrating that an AI-designed antigen is safe to put into humans and generates a measurable immune response. That is a necessary first step; it is not a finished product.
Researchers at Yesil Science noted: "Phase 1 trials are small and only measure safety and initial immune markers. While the AI successfully predicted stable targets, coding a vaccine is only the first step."
The Phase 2 trial, planned by the University of Cambridge and DIOSynVax, will assess immune responses in a wider and more diverse population and will be the more informative step toward understanding whether this approach can deliver on its promise.
Who Faces the Greatest Risk Without Updated COVID Vaccination Now?
- Adults 65 and older, who face the highest risk of severe COVID outcomes
- Immunocompromised individuals
- People with chronic lung, heart, or kidney disease
- Anyone who has not received a COVID vaccine or booster in the past six to 12 months
These populations should receive the currently available COVID vaccine this fall — not wait for a universal vaccine that is years from clinical availability.
What You Can Do Now
- Do not delay your current COVID vaccination to wait for the universal vaccine. It is a Phase 1 result in 39 people — public availability is at minimum three to seven years away.
- Updated COVID-19 vaccines for the 2026–2027 season are expected in late summer or early fall. Talk to your doctor about timing, particularly if you are in a high-risk group.
- Follow the development of pEVAC-PS through future trial results and publications for genuine updates on the science.
- If you are a researcher or clinician with interest in AI-driven vaccine platforms, the full Phase 1 results are published in the Journal of Infection (June 2026, Vol. 92 No. 6).
Cost and Access: What Patients Should Know
Annual COVID vaccines remain available and are expected to be covered by most insurance plans as preventive services. For uninsured Americans, CDC vaccination programs and community health centers provide COVID vaccines at reduced or no cost.
What Happens Next
The University of Cambridge and DIOSynVax have announced plans for a Phase 2 trial to evaluate immune responses in a broader, more diverse population. No timeline for Phase 2 enrollment or results has been publicly announced. MedicalDaily will report on Phase 2 results when they are published.
The Bottom Line
An AI-designed universal coronavirus vaccine has safely entered human testing, generating immune responses against multiple coronavirus strains in a small group of healthy adults. This is a real scientific step forward and proof of concept for AI-designed vaccines. But it is the first of several difficult steps that typically take years. Get your current COVID booster this fall, and watch for Phase 2 results in 2027 or beyond.
References
- ScienceDaily — AI-Designed Universal Coronavirus Vaccine Passes First Human Trial (June 5, 2026)
- Science Times — World First: Scientists Test an AI-Designed Universal Coronavirus Vaccine in Humans
- Open Access Government — AI-Designed Universal Vaccine Candidate Passes First Human Trial
- Dr. Kumar Discovery — An AI-Designed Universal Coronavirus Vaccine Passes Its First Human Test
- The Pharma Navigator — AI-Designed Universal Coronavirus Vaccine Passes First Human Trial
